866-997-4948(US-Canada Toll Free)

Metastatic Biliary Tract Cancer - Pipeline Review, H2 2015

Published By :

Global Markets Direct

Published Date : Aug 2015

Category :

Cancer

No. of Pages : 53 Pages

Metastatic Biliary Tract Cancer - Pipeline Review, H2 2015

Summary

Global Markets Directs, Metastatic Biliary Tract Cancer - Pipeline Review, H2 2015, provides an overview of the Metastatic Biliary Tract Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Biliary Tract Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Biliary Tract Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Biliary Tract Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Biliary Tract Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Biliary Tract Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Biliary Tract Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Biliary Tract Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Biliary Tract Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Biliary Tract Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Metastatic Biliary Tract Cancer - Overview 7
Pipeline Products for Metastatic Biliary Tract Cancer - Comparative Analysis 8
Metastatic Biliary Tract Cancer - Therapeutics under Development by Companies 9
Metastatic Biliary Tract Cancer - Pipeline Products Glance 10
Clinical Stage Products 10
Metastatic Biliary Tract Cancer - Products under Development by Companies 11
Metastatic Biliary Tract Cancer - Companies Involved in Therapeutics Development 12
Array BioPharma Inc. 12
AstraZeneca Plc 13
GlaxoSmithKline Plc 14
Novartis AG 15
OncoTherapy Science, Inc. 16
Metastatic Biliary Tract Cancer - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 24
Drug Profiles 26
binimetinib - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
OCVC-01 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
selumetinib sulfate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
trametinib dimethyl sulfoxide - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Metastatic Biliary Tract Cancer - Recent Pipeline Updates 41
Metastatic Biliary Tract Cancer - Discontinued Products 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List of Tables
Number of Products under Development for Metastatic Biliary Tract Cancer, H2 2015 7
Number of Products under Development for Metastatic Biliary Tract Cancer - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 10
Products under Development by Companies, H2 2015 11
Metastatic Biliary Tract Cancer - Pipeline by Array BioPharma Inc., H2 2015 12
Metastatic Biliary Tract Cancer - Pipeline by AstraZeneca Plc, H2 2015 13
Metastatic Biliary Tract Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015 14
Metastatic Biliary Tract Cancer - Pipeline by Novartis AG, H2 2015 15
Metastatic Biliary Tract Cancer - Pipeline by OncoTherapy Science, Inc., H2 2015 16
Assessment by Monotherapy Products, H2 2015 17
Assessment by Combination Products, H2 2015 18
Number of Products by Stage and Target, H2 2015 20
Number of Products by Stage and Mechanism of Action, H2 2015 22
Number of Products by Stage and Route of Administration, H2 2015 23
Number of Products by Stage and Molecule Type, H2 2015 25
Metastatic Biliary Tract Cancer Therapeutics - Recent Pipeline Updates, H2 2015 41
Metastatic Biliary Tract Cancer - Discontinued Products, H2 2015 51

List of Figures
Number of Products under Development for Metastatic Biliary Tract Cancer, H2 2015 7
Number of Products under Development for Metastatic Biliary Tract Cancer - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 10
Assessment by Monotherapy Products, H2 2015 17
Number of Products by Top 10 Targets, H2 2015 19
Number of Products by Stage and Top 10 Targets, H2 2015 19
Number of Products by Top 10 Mechanism of Actions, H2 2015 21
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 21
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 23
Number of Products by Top 10 Molecule Types, H2 2015 24
Number of Products by Stage and Top 10 Molecule Types, H2 2015 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *